Zevra Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$106M
Cost of Revenue
$16M
R&D
$13M
SG&A
$78M
D&A
$4M
Operating Income
$-63M
EBITDA
$-59M
Interest Expense
$8M
Other Income/Expense
$158M
Pretax Income
$87M
Tax Provision
$3M
Net Income
$83M
Operating Margin
-59.1%
Net Margin
78.2%
Effective Tax Rate
4.0%
Deferred Tax Assets
$187K
Deferred Tax Liabilities
$173K
DTA Valuation Allowance
$91M
Tax Credit Carryforwards
$941K
NOL Carryforwards
$63M
ETR (Continuing Operations)
4.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.1%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
$747K
Revenue YoY Variation
350.9%
Income YoY Variation
27.7%